Continuous Intrajejunal Levodopa-Carbidopa Infusion in Parkinson's Disease Associated with 22q11.2 Deletion Syndrome: A Case Series.
Continuous Intrajejunal Levodopa-Carbidopa Infusion in Parkinson's Disease Associated with 22q11.2 Deletion Syndrome: A Case Series.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Nancy, FR · Author affiliation
Université de Lorraine, Inserm, NGERE, Nancy, France.Location evidence
FR · Author affiliation · country only
Service de Neurologie CHR de Mercy, Ars-Lequenexy, France.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
BACKGROUND: 22q11.2 deletion syndrome (22q11DS) is a multisystem genetic disorder associated with a significantly increased risk of early-onset Parkinson's disease (EOPD). Management is challenging because psychiatric and cognitive comorbidities often limit advanced therapies such as deep brain stimulation (DBS). CASES: We report 2 patients with 22q11DS who developed EOPD at about age 30 with prominent psychiatric manifestations. In both cases, diagnosis of 22q11DS was delayed until genetic testing was performed for atypical parkinsonism associated with intellectual disability and dysmorphic features. Severe motor fluctuations and dyskinesia developed early. Because of psychiatric vulnerability, DBS and dopamine agonists were considered unsuitable. Continuous intrajejunal levodopa-carbidopa infusion (LCIG [levodopa-carbidopa intestinal gel]) was initiated, which led to sustained improvement in motor fluctuations and functional status, although individualized dose adjustments were required. CONCLUSIONS: LCIG may represent a valuable therapeutic option in selected patients with 22q11DS-associated Parkinson's disease when psychiatric comorbidity limits other advanced therapies.